Literature DB >> 16251319

Spontaneous conversion to quinolone and fluoroquinolone resistance among wild-type Escherichia coli isolates in relation to phylogenetic background and virulence genotype.

James R Johnson1, Brian Johnston, Michael A Kuskowski, Raul Colodner, Raul Raz.   

Abstract

Human clinical isolates of Escherichia coli that are resistant to quinolone or fluoroquinolone agents typically exhibit fewer extraintestinal virulence factors (VFs) than susceptible isolates, along with a different phylogenetic background. To experimentally assess the basis for this as-yet-unexplained phenomenon, 40 E. coli strains (20 E. coli Reference collection members and 20 Israeli cystitis isolates) were subjected to serial selective passaging to obtain derivatives resistant to nalidixic acid (NA) and ciprofloxacin (C). PCR-based VF profiling and phylotyping were performed on the parents and their respective resistant derivatives. All 40 susceptible parent strains yielded NA- and C-resistant derivatives after a median of 6 (range, 4 to 12) serial selective passages on agar plates containing increasing concentrations of NA and C. The numbers of passages required for resistance did not differ by collection origin, phylogenetic group, basal VF profile, source (urine versus fecal), or host group (human versus animal). With the development of C resistance, only one VF was lost in a single strain. Resistant derivatives exhibited the same phylotype as their susceptible parents. These findings suggest that the sparse VF profiles and the low-virulence phylogenetic background of NA- and C-resistant E. coli clinical isolates probably are not attributable to the loss of VFs from intrinsically high-virulence strains during conversion to resistance or to enhanced emergence of drug resistance among intrinsically low-virulence strains. A more likely explanation is the importation of resistant strains from an as-yet-undefined low-virulence external selection reservoir.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16251319      PMCID: PMC1280159          DOI: 10.1128/AAC.49.11.4739-4744.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Clonal origin, virulence factors, and virulence.

Authors:  J R Johnson; M Kuskowski
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

2.  Identification of reduced fluoroquinolone susceptibility in Escherichia coli: a herald for emerging resistance.

Authors:  F J Chen; L C McDonald; M Ho; H J Lo
Journal:  J Antimicrob Chemother       Date:  2001-12       Impact factor: 5.790

3.  Antimicrobial resistance in Escherichia coli causing urinary tract infections in Costa Rica: a clinical dilemma.

Authors:  David N Williams; Mark R Sannes; Alison A Eckhoff; Phillip K Peterson; James R Johnson; Mark R Sannes; Marielos San Román; Nury Mora; Javier Moya
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283

4.  Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis.

Authors:  James R Johnson; Michael A Kuskowski; Timothy T O'bryan; Raul Colodner; Raul Raz
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Contamination of retail foods, particularly turkey, from community markets (Minnesota, 1999-2000) with antimicrobial-resistant and extraintestinal pathogenic Escherichia coli.

Authors:  James R Johnson; Parissa Delavari; Timothy T O'Bryan; Kirk E Smith; Sita Tatini
Journal:  Foodborne Pathog Dis       Date:  2005       Impact factor: 3.171

6.  Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001.

Authors:  James R Johnson; Michael A Kuskowski; Abby Gajewski; Daniel F Sahm; James A Karlowsky
Journal:  J Infect Dis       Date:  2004-10-07       Impact factor: 5.226

7.  Are quinolone-resistant uropathogenic Escherichia coli less virulent?

Authors:  Jordi Vila; Karine Simon; Joaquin Ruiz; Juan P Horcajada; Maria Velasco; Margarita Barranco; Antonio Moreno; Josep Mensa
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

8.  Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance.

Authors:  Joel N Maslow; Ebbing Lautenbach; Thomas Glaze; Warren Bilker; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli.

Authors:  K Huotari; E Tarkka; V Valtonen; E Kolho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-18       Impact factor: 3.267

10.  Phylogenetic background and virulence profiles of fluoroquinolone-resistant clinical Escherichia coli isolates from the Netherlands.

Authors:  James R Johnson; Cindy van der Schee; Michael A Kuskowski; Wil Goessens; Alex van Belkum
Journal:  J Infect Dis       Date:  2002-11-22       Impact factor: 5.226

View more
  10 in total

1.  Virulence factors in Escherichia coli.

Authors:  James R Johnson
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

2.  Characterization of non-O157 shiga toxin-producing Escherichia coli isolates from healthy fat-tailed sheep in southeastern of Iran.

Authors:  Reza Ghanbarpour; Mojtaba Kiani
Journal:  Trop Anim Health Prod       Date:  2012-09-27       Impact factor: 1.559

3.  Cpa, the outer membrane protease of Cronobacter sakazakii, activates plasminogen and mediates resistance to serum bactericidal activity.

Authors:  A A Franco; M H Kothary; G Gopinath; K G Jarvis; C J Grim; L Hu; A R Datta; B A McCardell; B D Tall
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

4.  Virulence potential of Escherichia coli isolates from skin and soft tissue infections.

Authors:  Ziva Petkovsek; Kristina Elersic; Marija Gubina; Darja Zgur-Bertok; Marjanca Starcic Erjavec
Journal:  J Clin Microbiol       Date:  2009-04-08       Impact factor: 5.948

5.  Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance.

Authors:  Gabriella Piatti; Alessandro Mannini; Maria Balistreri; Anna Maria Schito
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

6.  Uropathogenic Escherichia coli in Iran: serogroup distributions, virulence factors and antimicrobial resistance properties.

Authors:  Hassan Momtaz; Azam Karimian; Mahboobeh Madani; Farhad Safarpoor Dehkordi; Reza Ranjbar; Meysam Sarshar; Negar Souod
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-04-29       Impact factor: 3.944

7.  Linking Genomo- and Pathotype: Exploiting the Zebrafish Embryo Model to Investigate the Divergent Virulence Potential among Cronobacter spp.

Authors:  Athmanya K Eshwar; Ben D Tall; Jayanthi Gangiredla; Gopal R Gopinath; Isha R Patel; Stephan C F Neuhauss; Roger Stephan; Angelika Lehner
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

8.  The Roles of Two Type VI Secretion Systems in Cronobacter sakazakii ATCC 12868.

Authors:  Min Wang; Hengchun Cao; Qian Wang; Tingting Xu; Xi Guo; Bin Liu
Journal:  Front Microbiol       Date:  2018-10-22       Impact factor: 5.640

9.  Virulence profiles, phylogenetic background, and antibiotic resistance of Escherichia coli isolated from turkeys with airsacculitis.

Authors:  Marcos Paulo Vieira Cunha; Maria Gabriela Xavier de Oliveira; Mirela Caroline Vilela de Oliveira; Ketrin Cristina da Silva; Cleise Ribeiro Gomes; Andrea Micke Moreno; Terezinha Knöbl
Journal:  ScientificWorldJournal       Date:  2014-07-02

10.  Biofilm formation, antimicrobial susceptibility, serogroups and virulence genes of uropathogenic E. coli isolated from clinical samples in Iran.

Authors:  Elahe Tajbakhsh; Parvin Ahmadi; Elham Abedpour-Dehkordi; Nazila Arbab-Soleimani; Faham Khamesipour
Journal:  Antimicrob Resist Infect Control       Date:  2016-04-01       Impact factor: 4.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.